We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 12 of 162 for:    curcumin

18-Month Study of Curcumin (Curcumin)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01383161
Recruitment Status : Active, not recruiting
First Posted : June 28, 2011
Last Update Posted : May 4, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:

This project is designed to study the effects of the dietary supplement curcumin on age-related cognitive impairment. In particular, the study seeks to determine the effects of curcumin on cognitive decline and the amount of abnormal amyloid protein in the brain. Genetic risk will also be studied as a potential predictor of cognitive decline.

Subjects will be randomly assigned to one of two treatment groups: either a placebo or the curcumin supplement (465 milligrams of Theracurmin™ of which 30 mg is curcumin). The investigators expect the people receiving the curcumin supplement to show less evidence of decline and fewer after 18 months than those receiving the placebo. The investigators believe cognitive decline and treatment response will vary according to a genetic risk for Alzheimer's.

The investigators will study 132 subjects with memory complaints aged 50-90 years. Initially, subjects will undergo a clinical assessment, an MRI and a blood draw to determine genetic risk and to rule out other neurodegenerative disorders linked to memory complaints. Subsequently, subjects will undergo an -(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP)PET scan and a baseline neuropsychological assessment to confirm MCI or normal aging diagnosis. Once enrolled, subjects will begin taking the supplement (either curcumin or a placebo), and be asked to return every three months for regular MRIs and review sessions. Every 6 months, subjects will also neuropsychological assessments. At the conclusion of the study, subjects will be asked to complete a final neuropsychological assessment, MRI scan, PET scan and blood draw. Additional blood will be drawn at baseline and at 18 months and frozen to assess inflammatory markers if outcomes are positive.

FDDNP-PET scans will be used to measure the amount of abnormal amyloid plaque- and tau tangle- proteins in the brain; the MRIs will be used to monitor supplement side effects and measure brain structure; the neuropsychological assessments will monitor rates of cognitive decline; the blood draws will be used to test levels of inflammatory markers.

Condition or disease Intervention/treatment Phase
Age-associated Cognitive Impairment Mild Cognitive Impairment (MCI) Drug: Curcumin Other: Placebo Phase 2

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 132 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: 18-Month Double-Blind, Placebo-Controlled Study of Curcumin
Study Start Date : March 2012
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : July 2018
Arms and Interventions

Arm Intervention/treatment
Active Comparator: Curcumin
Theracurmin (180mg/day)
Drug: Curcumin
Six 465 milligram capsules (containing 30 mg of curcumin each) per day for 18 months.
Other Name: Theracurmin CR-031P™ (Dietary Supplement)
Placebo Comparator: Sugar Pill Other: Placebo
Six 465 milligram capsules per day for 18 months.

Outcome Measures

Primary Outcome Measures :
  1. Change in cognitive testing results from Baseline to 6, 12 and 18 months. [ Time Frame: 6, 12 and 18 months. ]
    People with age-related cognitive decline (i.e., MCI, AAMI or normal aging), who receive curcumin 90 mg twice each day will show less evidence of cognitive decline (as measured with neuropsychological assessments) than those receiving placebo after 18 months.

Secondary Outcome Measures :
  1. Correlation of primary outcomes to gentoype [ Time Frame: 18 months ]
    Cognitive change, FDDNP-PET measures, and treatment response will vary according to genotypes found to influence age at dementia onset (e.g., apolipoprotein E [APOE] TOMM40).

  2. Change in level of inflammatory markers in blood from Baseline to 18 months. [ Time Frame: 18 months ]
    People with age-related cognitive decline, who receive curcumin 90 mg twice each day, will show decreased measures of inflammation in the blood compared with those receiving placebo after 18 months.

  3. Change in amount of brain amyloid protein in subjects received curcumin from Baseline to 18 months. [ Time Frame: 18 months ]
    People with age-related cognitive decline who receive an oral dose of curcumin 90 mg twice each day will show less build-up of plaques and tangles (as measured with FDDNP-PET imaging) than those receiving placebo after 18 months.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Agreement to participate in the 18-month double-blind, placebo-controlled clinical trial of curcumin.
  2. Diagnostic criteria for mild cognitive impairment (MCI) or any age related memory decline according to standard criteria (Petersen et al, 2001; Crook et al, 1986).
  3. Age 50 to 90 years.
  4. No significant cerebrovascular disease: modified Ischemic Score of < 4 (Rosen et al, 1980).
  5. Adequate visual and auditory acuity to allow neuropsychological testing.
  6. Screening laboratory tests and EKG without significant abnormalities that might interfere with the study.

Exclusion Criteria

  1. Diagnosis of probable Alzheimer's disease (AD) or any other dementia (e.g., vascular, Lewy body, frontotemporal) (McKhann et al, 1984).
  2. Evidence of other neurological or physical illness that can produce cognitive deterioration. Volunteers with a history of stroke, TIA, carotid bruits, or lacunes on MRI scans will be excluded.
  3. Inability to undergo MRI.
  4. Evidence of Parkinson's disease as determined by the motor examination (items 18-31) of the Unified Parkinson's Disease Rating Scale (Fahn et al, 1987).
  5. History of myocardial infarction within the previous year, or unstable cardiac disease.
  6. Uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100).
  7. History of significant liver disease, clinically-significant pulmonary disease, diabetes, or cancer.
  8. Current diagnosis of any major psychiatric disorder according to the DSM-IV TR criteria (APA, 2000).
  9. Current diagnosis or history of alcoholism or substance addiction.
  10. Regular use of any medication that may affect cognitive functioning including: centrally active beta-blockers, narcotics, Clonidine, anti-Parkinsonian medications, antipsychotics, benzodiazepines, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anti-convulsants, or Warfarin. Occasional chloral hydrate use will be allowed, but discouraged, for insomnia.
  11. Use of more than one multivitamin per day. Vitamins other than the standard multivitamin supplement will not be allowed.
  12. Use of medications known to affect FDDNP-PET binding (e.g., ibuprofen, naproxen).
  13. Use of more than one daily baby aspirin (81mg) and/or use of any medication containing curcumin.
  14. Use of cognitive enhancing supplements (e.g. Ginkgo biloba).
  15. Use of any investigational drugs within the previous month or longer, depending on drug half-life.
  16. Pregnancy.
  17. HIV infection.
  18. Evidence of vasogenic edema; specifically, evidence of more than 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite") or a single area of superficial siderosis), or evidence of a prior macrohemorrhage at screening or baseline.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01383161

United States, California
UCLA Longevity Center
Los Angeles, California, United States, 90095
Sponsors and Collaborators
University of California, Los Angeles
Principal Investigator: Gary W Small, M.D. UCLA Longevity Center
More Information

Additional Information:
[No authors listed] Consensus report of the Working Group on:

Responsible Party: Gary Small, MD, Principal Investigator, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01383161     History of Changes
Other Study ID Numbers: 11-001740
IND 112714 ( Other Identifier: FDA )
First Posted: June 28, 2011    Key Record Dates
Last Update Posted: May 4, 2017
Last Verified: May 2017

Keywords provided by Gary Small, MD, University of California, Los Angeles:
Cognitive Impairment
Brain Imaging

Additional relevant MeSH terms:
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action